Background/Aims: Hyaluronic acid (HA) regulates cell adhesion, migration and proliferation in various cancers. The clinical implications of HA in resected head and neck squamous cell carcinoma have not been elucidated. We investigated the clinical significance and prognostic value of the expression of tumoral and stromal HA and its related proteins in oropharyngeal and oral cavity cancer. Methods: Resected tissues from oropharyngeal or oral cavity cancer patients undergoing surgery were analysed in tissue microarrays divided into stroma and cancer panels. The expression levels of HA, HA synthases and hyaluronidases were also assessed by immunohistochemistry. Results: A total of 160 resected oropharyngeal or oral cavity cancer tissues were analysed. Stromal HA expression was observed more frequently in human papilloma virus (HPV)-negative tumors, but other clinicopathological characteristics did not differ. In patients with HPV-negative oral cavity cancers, high stromal HA expression was associated with significantly shorter recurrence-free survival and overall survival compared with low stromal HA expression. The expression of HA in both tumors and stroma was significantly correlated with poorer outcomes than other combinations in patients with HPV-negative oral cavity cancers. However, these prognostic roles of HA were not observed in patients with HPV-negative oropharyngeal cancers. In the HPV-stratified multivariate analysis, high stromal HA expression remained an independent indicator of poor prognosis in terms of recurrence-free survival. Conclusions: High stromal HA and expression of HA in both tumors and stroma were correlated with poor prognosis in HPV-negative oral cavity cancer, but not in HPV-negative oropharyngeal cancers.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the most common malignant neoplasm of the head and neck [1] . A multimodal treatment strategy has been widely considered the standard treatment for locally advanced HNSCC. With recent advancements in our understanding of the molecular biology of HNSCC, agents www.kjim.org https://doi.org/10.3904/kjim. 2018.203 targeting specific molecular markers, such as epidermal growth factor receptor, have also been widely used with cytotoxic chemotherapy or radiotherapy to improve patient survival in the setting of locally advanced and recurrent HNSCC [2] , but the survival of HNSCC patients is still unsatisfactory. The tumor microenvironment associated with the process of HNSCC has been attracting attention in investigations of effective prognostic factors in HNSCC [3] .
The tumor microenvironment is composed of cancer-associated fibroblasts, immune cells, and other stromal cells around the cancer cell extracellular matrix (ECM), which includes cell-adhesion molecules and ligands and plays a role in tissue organisation [4] . Hyaluronic acid (HA), composed of alternating N-acetylglucosamine and glucuronic acid units, is one of the major carbohydrates in the ECM. HA-family molecules include HA-synthase, HA receptors, and hyaluronidases (HAases). HA is synthesised by HA synthases (HAS1, HAS2, and HAS3) and degraded by HAases (such as HYAL1) [5, 6] . There are six HAases in the human genome, and HYAL1 and HYAL2 have the highest enzymatic activity. HA participates in tumor cell invasion and metastasis, and regulates cell proliferation, migration, and angiogenesis by interacting with specific cell-surface receptors, including CD44 and the receptor of HA-mediated motility [4] .
HA expression is known to be more abundant in stroma than in cancer cells, in various carcinomas [7] . As a prognostic factor, although HA in neoplastic cells predicted poor survival in patients with various cancers [8, 9] , elevated HA expression in tumor stroma also predicted poor survival in patients with breast cancer or prostate cancer [10] . However, there have been few reports on the prognostic significance of HA in oropharyngeal squamous cell carcinoma (OPSCC) or oral cavity squamous cell carcinoma (OSCC). In this study, we investigated the clinical significance and prognostic value of the expression of HA and its related molecules in patients with OPSCC and OSCC who underwent surgical resection.
METHODS

Patients
We retrospectively analysed the clinical and patholog- 
Tissue microarrays
For tissue microarray (TMA) analyses, two representative tumor areas were selected on haematoxylin and eosin (H&E)-stained slides. Duplicate cylindrical cores with 2-mm diameters were obtained from morphologically representative tissues of each tumor paraffin block using a manual tissue arrayer (SuperBioChips Laboratories, Seoul, Korea) and assembled in a TMA format. A section from each TMA block was stained with H&E and subjected to histological examination. Sections 4-μm in thickness were used for immunohistochemical staining.
The Korean Journal of Internal Medicine Vol. 35, No. 2, March 2020 3, strongly positive. The proportion was evaluated as positive tumor cell percentage. The histological score (H score; 0 to 300) was calculated by multiplying the intensity and proportion of expression. To determine the optimal cut-off values for survival prediction, a maximally selected rank statistic test was performed using the R Maxstat Package version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria). As a result, high expression was determined as follows: H score > 10 for tumoral HA expression, > 40 for tumoral HYAL1 expression, and > 30 for tumoral HAS2 expression. In tumor stromal expression, the following values were considered positive: H score > 0 for stromal HA expression, and > 10 for stromal HYAL1 expression. To assess human papilloma virus (HPV) status, p16 immunostaining was evaluated and strong nuclear and cytoplasmic staining in ≥ 75% of the tumor cells indicated positive expression. The results were analysed by a board-certified pathologist (S.A.H.) who was blinded to the clinical data.
HAS1 and HAS2 gene expression according to mutational status of various genes in The Cancer Genome Atlas HNSCC database
To identify associations between the HAS1 or HAS2 genes and various mutations and clinical features in HNSCC, the open access data tier generated by The Cancer Genome Atlas (TCGA) research network was used. mRNA expression data, mutation annotation files and clinical data were downloaded from the TCGA data portal (https://tcgadata.nci.nih.gov/tcga/). All mRNA expression data were log2-transformed. The epithelial-mesenchymal transition (EMT) score for each tumor was defined as the sum of the expression of well-known mesenchymal marker genes minus the expression of known epithelial genes, which are based on a previously reported expression signature of 76 genes [11] .
Statistical analysis
Clinicopathological characteristics are presented as medians (range) for continuous variables or numbers (percentage) for categorical variables. Comparisons between two groups were performed using Student's unpaired t test or the chi-square test. Recurrence-free survival (RFS) was measured from the date of surgery to the date of recurrence or censored at the last follow-up date. Overall survival (OS) was measured from the date of surgery until death resulting from any cause or the last censored date during follow-up. RFS and OS were calculated using the Kaplan-Meier method, and differences in survival between groups were compared by the logrank test. Cox proportional hazards regression models were used to investigate the significance of prognostic factors. Variables with p < 0.25 in the univariate model and/or variables associated with prognosis in HNSCC were included in the multivariate model. A backward elimination process was used to develop the final multivariate model, and adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. A p < 0.05 was considered statistically significant. All statistical analyses were performed using the R statistical software package version 3.2.3 (R Foundation for Statistical Computing).
RESULTS
Baseline characteristics
A total of 160 tumor specimens were included and analysed in this study. The baseline characteristics of the 160 patients are summarised in Table 1 . The median age was 56 years (range, 26 to 90), and 78.8% were male. A total of 101 patients (64.3%) were ever-smokers. Pathological analyses revealed that 130 patients (81.8%) were classified as stage T1 or T2, 80 (50.0%) as stage N2 and 105 (65.6%) as pathological stage III or IV. Based on p16 immunostaining results, 33 patients (21.9%) were considered HPV-positive. For primary treatment, 84 patients (52.5%) received surgery alone, and 76 patients (47.5%) received adjuvant treatment after surgery. Standard indications for adjuvant treatment included multiple lymph node involvement, a close or positive resection margin or the presence of extracapsular spread. Adjuvant treatments included radiotherapy alone (n = 40), platinum-based chemotherapy (n = 4), or concurrent chemoradiotherapy with cisplatin and/or fluorouracil (n = 32).
HA family protein expression and relationships with clinicopathological findings
Cytoplasmic expression of HA, HYAL1 and HAS2 was observed. HA and HYAL1 expression in the tumor stroma was only found when tumor cells were also positive ( Fig. 1 cules were dichotomised based on optimal cut-off values for clinical outcomes. High tumor cell expression of HA (H score > 10) was found in 47.5% of samples (n = 76), high expression of HYAL1 (H score > 40) in 38.7% (n = 62) and high HAS2 (H score > 30) in 10.6% (n = 17). Positive stromal expression of HA (any expression in the tumor stroma) was found in 19.4% of patients (n = 31), and positive HYAL1 expression (H score > 10) was found in 10.0% (n = 16). No HAS2 expression was observed in stromal tissues. Positive HA expression in tumor stroma was significantly correlated with tumoral HA expression (p < 0.001) and stromal HYAL1 expression (p = 0.016) (Table 2). The relationship between stromal HA expression and clinicopathological findings was explored ( Table 3 ). In all cases, stromal HA expression was not significantly correlated with HPV infection, but displayed a trend, and no significant differences were observed between stromal HA expression and age, gender, primary tumor site, histological differentiation, or lymph node metastasis.
Clinicopathological factors associated with prognosis stratified by HPV status
During the median follow-up of 59.6 months (range, 2.2 to 241.3), 56 patients (35.0%) developed tumor recurrence, and 86 (53.7%) died from any cause. Recurrence patterns included local recurrence in 40 cases (19.6%), distant recurrence in 17 cases (8.3%) and both local and distant recurrence in six cases (2.9%). The overall 5-year RFS rate for patients was 28.2%. The median RFS time was 14.3 months (range, 11.6 to 17.0) for all patients. HPV-related HNSCC has a molecular, epidemiological and clinical profile that is distinct from classical tobacco and/or alcohol-associated HNSCCs [12] , and HPV infection is a well-known powerful predictive and prognostic indicator in HNSCC, especially in oropharyngeal cancer [12] . Therefore, to eliminate the influence of HPV infection on prognosis, we performed HPV-stratified analyses to assess the independent prognostic value of the HA family. Based on the univariate analyses, predictors of RFS included advanced pT stage (p = 0.001), advanced pN stage (p = 0.001), lymphatic invasion status (p = 0.017), smoking status (p = 0.041), and poor differentiation (p = 0.048) ( Table 4 ). In the multivariate analysis of RFS, advanced pT stage (HR, 2.591; p = 0.011) and advanced pN stage (HR, 2.232; p = 0.048) remained significant prog- (Table 5 ). Of these factors, age (HR, 1.038; p = 0.004), advanced pT stage (HR, 2.425; p = 0.002), and advanced pN stage (HR, 1.833; p = 0.023) were identified as independent prognostic factors of poor OS in multivariate analysis.
Prognostic role of HA family molecule expression stratified by HPV status
In patients with HPV-positive oral cavity or oropharyngeal cancers, the expression of HA family molecules in tumors and stroma showed no significant correlations with RFS or OS (oral cavity cancer: RFS, p = 0.414; OS, p = 0.886; oropharyngeal cancer: RFS, p = 0.581; OS, p = 0.519). Regarding clinical outcomes of patients with HPV-negative oral cavity cancers, high stromal HA expression resulted in significantly shorter RFS (p < 0.001, Fig. 2A ) and OS (p = 0.040, Fig. 2C ) compared with low stromal HA expression as determined by log-rank test.
In patients with HPV-negative oropharyngeal cancers; however, stromal HA expression showed no significant correlation with RFS (p = 0.453, Fig. 2B ) or OS (p = 0.230, Fig. 2D) . A significant and strong relationship between tumor and stromal HA expression was observed; therefore, we analysed the expression of HA in tumors and stroma. In patients with HPV-negative oral cavity cancers, the expression of HA in both tumors and stroma was significantly correlated with poorer outcomes than other combinations (RFS, p = 0.069, Fig. 3A ; OS, p = 0.015, Fig. 3C ), but this was not the case in patients with HPV-negative oropharyngeal cancers (RFS, p = 0.742, Fig.  3B ; OS, p = 0.671, Fig. 3D ). In the HPV-stratified multivariate analysis, high stromal HA expression remained an independent indicator of poor prognosis in terms of RFS (HR, 2.712; 95% CI, 1.323 to 5.56; p = 0.006) ( Table 4) , but not OS (Table 5 ).
HAS1 and HAS2 gene expression in the TCGA database
The gene expression levels of HAS1 and HAS2 were ana-lysed in HNSCC samples (n = 279) from the TCGA database. We compared HAS1 or HAS2 gene expression with primary site, smoking status and HPV status. HAS1 and HAS2 mRNA upregulation was enriched in oral cavity and HPV-negative cancers (oral cavity: p < 0.001 and p < 0.001, respectively, Fig. 4A ; HPV status: p = 0.004 and p = 0.005, respectively, Fig. 4B ). HAS1 and HAS2 gene expression were significantly correlated with EMT score (Fig. 4C ).
DISCUSSION
In this study, we investigated the clinical significance of HA-family molecules in patients with oropharyngeal or oral cavity cancer receiving curative surgical resection. Although there were no significant correlations between HA expression and clinicopathological findings, we found that high stromal HA expression was an independent poor prognostic factor in terms of RFS. According to HPV-stratified analysis, patients with high stromal HA expression in HPV-negative oral cavity cancer showed significantly shorter RFS and OS. However, HYAL1 and HAS2 expression showed no significant associations with RFS or OS. These observations suggested that the prognostic impact of stromal HA expression is much stronger in HPV-negative tumors than in HPV-positive tumors.
The tumor microenvironment is composed of ECM and numerous stromal cells. The importance of the tumor microenvironment in cancer initiation and progression is well established. Changes in the ECM occur during cancer development, enabling tumor cells to disseminate [13] . The glycosaminoglycan HA is one of the main components of the ECM. HA levels are maintained through a balance of synthesis by HAS and degradation by the enzyme HYAL1. The roles of HA-family molecules in cancer have been widely investigated. In cancer patients, HA concentrations are usually higher in malignant tumors than in benign and normal tissues. Several studies have reported a correlation between HA concentration in tumors or stroma and tumor aggression [14] . HA synthase and/or HYAL have been suggested to contribute to tumor cell proliferation, motility and invasion by controlling the level of HA and activating intracellular signalling pathways initiated by HA inter- actions with HA receptors. Previous studies found high levels of HA around tumor cells or within the tumor stroma. The levels of HA in tumor cells and/or stroma were correlated with overall tumor aggressiveness and increased cell migration and proliferation in various types of cancer [14] . Auvinen et al. [10] reported that both HA associated with tumor cells and stromal HA were independent prognostic factors for OS in patients with breast cancer. Lokeshwar et al. [15] reported that stromal-epithelial HA overexpres-sion may be linked with cancer progression. In addition, in gastric and colorectal cancers, high levels of HA in tumor cells was shown to be a poor prognostic factor associated with reduced survival [8, 9] . There have been few studies evaluating HA in head and neck cancer. Kosunen et al. [16] reported that homogeneous expression of HA in tumor epithelium was associated with better OS and disease-free survival compared with irregular HA expression. Hirvikoski et al. [17] reported the prognostic role of tumoral HA in laryngeal squamous cell carcino- The Korean Journal of Internal Medicine Vol. 35, No. 2, March 2020 ma using intensity scores for homogeneous or irregular staining. They showed that the irregular staining of HA in tumor cells of laryngeal squamous cell carcinoma trended toward poor disease-free survival, suggesting that an altered HA metabolism is associated with an aggressive growth pattern [17] . In the present study, we first identified an association between high stromal HA expression and poor prognosis in patients with HPV-negative oral cavity cancer. Interestingly, tumor stromal HA expression was only observed when tumor cells exhibited tumoral HA expression. Lokeshwar et al. [15] demonstrated that HA is localised almost exclusively in the stroma and its concentration increased considerably in tumor-associated stroma in prostate cancer, and both stromal fibroblasts and tumor epithelial cells from prostate cancer tissues showed elevated HA secretions. Based on these findings and the intimate crosstalk between tumors and the tumor microenvironment, HA expression may result from the interaction between tumors and tumor stroma. In this study, we observed 
